Skip to main content
. 2017 Dec 19;137(2):295–302. doi: 10.1007/s11060-017-2717-0

Table 3.

Median survival comparison between the discordant and concordant groups according to receptor profiles in patients with primary breast cancer and brain metastasis

Median survival (months) Log-rank test (p value)
ER conversion 0.853
 Discordant (n = 2) 4.9
 Concordant (n = 19) 22.8
PR conversion 0.310
 Discordant (n = 8) 15.4
 Concordant (n = 13) 30.1
HER2 conversion 0.389
 Discordant (n = 5) 21.4
 Concordant (n = 16) 22.8

ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2